Publications

Chen HJoyce, Poran A, Unni AM, Huang SXuelian, Elemento O, Snoeck H-W, Varmus H.  2019.  Generation of pulmonary neuroendocrine cells and SCLC-like tumors from human embryonic stem cells.. J Exp Med. 216(3):674-687.

Rath P, Huang C, Wang T, Wang T, Li H, Prados-Rosales R, Elemento O, Casadevall A, Nathan CF.  2013.  Genetic regulation of vesiculogenesis and immunomodulation in Mycobacterium tuberculosis.. Proc Natl Acad Sci U S A. 110(49):E4790-7.

Jiang Y, T Soong D, Wang L, Melnick AM, Elemento O.  2012.  Genome-wide detection of genes targeted by non-Ig somatic hypermutation in lymphoma.. PLoS One. 7(7):e40332.

Wolujewicz P, Aguiar-Pulido V, AbdelAleem A, Nair V, Thareja G, Suhre K, Shaw GM, Finnell RH, Elemento O, M Ross E.  2021.  Genome-wide investigation identifies a rare copy-number variant burden associated with human spina bifida.. Genet Med. 23(7):1211-1218.

Kassambara A, Jourdan M, Bruyer A, Robert N, Pantesco V, Elemento O, Klein B, Moreaux J.  2017.  Global miRNA expression analysis identifies novel key regulators of plasma cell differentiation and malignant plasma cell.. Nucleic Acids Res. 45(10):5639-5652.

Sun M, Zhao S, Gilvary C, Elemento O, Zhou J, Wang F.  2020.  Graph convolutional networks for computational drug development and discovery.. Brief Bioinform. 21(3):919-935.

Xie XP, Laks DR, Sun D, Poran A, Laughney AM, Wang Z, Sam J, Belenguer G, Fariñas I, Elemento O et al..  2020.  High-resolution mouse subventricular zone stem-cell niche transcriptome reveals features of lineage, anatomy, and aging.. Proc Natl Acad Sci U S A. 117(49):31448-31458.

Yusufova N, Kloetgen A, Teater M, Osunsade A, Camarillo JM, Chin CR, Doane AS, Venters BJ, Portillo-Ledesma S, Conway J et al..  2021.  Histone H1 loss drives lymphoma by disrupting 3D chromatin architecture.. Nature. 589(7841):299-305.

Ortega-Molina A, Boss IW, Canela A, Pan H, Jiang Y, Zhao C, Jiang M, Hu D, Agirre X, Niesvizky I et al..  2015.  The histone lysine methyltransferase KMT2D sustains a gene expression program that represses B cell lymphoma development.. Nat Med. 21(10):1199-208.

Popovic R, Martinez-Garcia E, Giannopoulou EG, Zhang Q, Zhang Q, Ezponda T, Shah MY, Zheng Y, Will CM, Small EC et al..  2014.  Histone methyltransferase MMSET/NSD2 alters EZH2 binding and reprograms the myeloma epigenome through global and focal changes in H3K36 and H3K27 methylation.. PLoS Genet. 10(9):e1004566.

Wen D, Banaszynski LA, Liu Y, Geng F, Noh K-M, Xiang J, Elemento O, Rosenwaks Z, C Allis D, Rafii S.  2014.  Histone variant H3.3 is an essential maternal factor for oocyte reprogramming.. Proc Natl Acad Sci U S A. 111(20):7325-30.

Liu Y, Choi DSoon, Sheng J, Ensor JE, Liang DHwang, Rodriguez-Aguayo C, Polley A, Benz S, Elemento O, Verma A et al..  2018.  HN1L Promotes Triple-Negative Breast Cancer Stem Cells through LEPR-STAT3 Pathway.. Stem Cell Reports. 10(1):212-227.

Rafii S, Kloss CC, Butler JM, Ginsberg M, Gars E, Lis R, Zhan Q, Josipovic P, Ding B-S, Xiang J et al..  2013.  Human ESC-derived hemogenic endothelial cells undergo distinct waves of endothelial to hematopoietic transition.. Blood. 121(5):770-80.

Hatzi K, Jiang Y, Huang C, Garrett-Bakelman F, Gearhart MD, Giannopoulou EG, Zumbo P, Kirouac K, Bhaskara S, Polo JM et al..  2013.  A hybrid mechanism of action for BCL6 in B cells defined by formation of functionally distinct complexes at enhancers and promoters.. Cell Rep. 4(3):578-88.

Campbell TL, De Silva EK, Olszewski KL, Elemento O, Llinás M.  2010.  Identification and genome-wide prediction of DNA binding specificities for the ApiAP2 family of regulators from the malaria parasite.. PLoS Pathog. 6(10):e1001165.

Nayar U, Sadek J, Reichel J, Hernandez-Hopkins D, Akar G, Barelli PJ, Sahai MA, Zhou H, Totonchy J, Jayabalan D et al..  2017.  Identification of a nucleoside analog active against adenosine kinase-expressing plasma cell malignancies.. J Clin Invest. 127(6):2066-2080.

Musselman K, Glynn S, Mosquera JMiguel, Elemento O, Sboner A, Beltran H, Holcomb K.  2019.  Identification of a therapeutic target using molecular sequencing for treatment of recurrent uterine serous adenocarcinoma.. Gynecol Oncol Rep. 28:54-57.

Davis M, Martini R, Newman L, Elemento O, White J, Verma A, Datta I, Adrianto I, Chen Y, Gardner K et al..  2020.  Identification of Distinct Heterogenic Subtypes and Molecular Signatures Associated with African Ancestry in Triple Negative Breast Cancer Using Quantified Genetic Ancestry Models in Admixed Race Populations.. Cancers (Basel). 12(5)

Demichelis F, Setlur SR, Banerjee S, Chakravarty D, Chen JYun Helen, Chen CX, Huang J, Beltran H, Oldridge DA, Kitabayashi N et al..  2012.  Identification of functionally active, low frequency copy number variants at 15q21.3 and 12q21.31 associated with prostate cancer risk.. Proc Natl Acad Sci U S A. 109(17):6686-91.

Durrans A, Gao D, Gupta R, Fischer KR, Choi H, Rayes TEl, Ryu S, Nasar A, Spinelli CF, Andrews W et al..  2015.  Identification of Reprogrammed Myeloid Cell Transcriptomes in NSCLC.. PLoS One. 10(6):e0129123.

Liu H, Murphy CJ, Karreth FA, Emdal KB, White FM, Elemento O, Toker A, Wulf GM, Cantley LC.  2018.  Identifying and Targeting Sporadic Oncogenic Genetic Aberrations in Mouse Models of Triple-Negative Breast Cancer.. Cancer Discov. 8(3):354-369.

Elemento O, Lefranc MPaule.  2003.  IMGT/PhyloGene: an on-line tool for comparative analysis of immunoglobulin and T cell receptor genes.. Dev Comp Immunol. 27(9):763-79.

Markowitz GJ, Havel LS, Crowley MJp, Ban Y, Lee SB, Thalappillil JS, Narula N, Bhinder B, Elemento O, Wong STc et al..  2018.  Immune reprogramming via PD-1 inhibition enhances early-stage lung cancer survival.. JCI Insight. 3(13)

Buqué A, Bloy N, Perez-Lanzón M, Iribarren K, Humeau J, Pol JG, Levesque S, Mondragon L, Yamazaki T, Sato A et al..  2020.  Immunoprophylactic and immunotherapeutic control of hormone receptor-positive breast cancer.. Nat Commun. 11(1):3819.

de Martino M, Zhuang D, Klatte T, Rieken M, Rouprêt M, Xylinas E, Clozel T, Krzywinski M, Elemento O, Shariat SF.  2014.  Impact of ERBB2 mutations on in vitro sensitivity of bladder cancer to lapatinib.. Cancer Biol Ther. 15(9):1239-47.